OLAI versus RLAI | Incremental (discounted) | ICER (discounted) | |||||
---|---|---|---|---|---|---|---|
Cost mean (SD) | LYs mean (SD) | QALYs mean (SD) | Relapses mean (SD) | Cost/QALY | Cost/relapse avoided | Cost/life year gained | |
Base case | -€2939.66 (300.83) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Revised OLAI dosing schedule (2 weekly starting dose & 4 weekly maintenance dose) | -€2810.58 (281.38) | 0.04 0.021) | 0.07 (0.018) | −0.41 (0.046) | Dominant | Dominant | Dominant |
Discount Rate set to 0% | -€3068.23 (321.06) | 0.04 (0.027) | 0.08 (0.020) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Discount rate set to 6% | -€981.51 (125.16) | 0.0001 (0.000) | 0.0005 (0.000) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Relapse rate of OLAI equal to RLAI (0.176) | -€2513.30 (286.30) | 0.04 (0.024) | 0.05 (0.018) | −0.34 (0.044) | Dominant | Dominant | Dominant |
Discontinuation of OLAI equal to RLAI (0.445) | -€1594.46 (324.59) | −0.003 (0.027) | −0.003 (0.019) | −0.07 (0.050) | €472796.00 | Dominant | €491207.00 |
Maximum number of switches set to 5 | -€2937.57 (314.19) | 0.04 (0.023) | 0.07 (0.017) | −0.42 0.050) | Dominant | Dominant | Dominant |
Maximum number of switches set to 10 | -€2947.24 (318.27) | 0.04 (0.022) | 0.07 (0.017) | −0.42 (0.052) | Dominant | Dominant | Dominant |
Cost of routine management1 increased 30% | -€3527.51 (371.13) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of routine management1 decreased 30% | -€2351.82 (232.74) | 0.04(0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Yearly adverse event rate of OLAI equals RLAI | -€2878.91 (319.59) | 0.04 (0.023) | 0.09 (0.016) | −0.41 (0.052) | Dominant | Dominant | Dominant |
Cost of administration increased 30% | -€3083.92 (303.46) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of administration decreased 30% | -€2795.41 (298.37) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of administration of OLAI equals RLAI | -€3392.17 (301.51) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Time Horizon 1 year | -€643.44 (116.98) | 0.02 (0.004) | 0.02 (0.003) | −0.11 (0.023) | Dominant | Dominant | Dominant |
Time Horizon 2 years | -€1402.48 (168.63) | 0.02 (0.009) | 0.03 (0.007) | −0.21 (0.031) | Dominant | Dominant | Dominant |
Time Horizon 3 years | -€2005.29 (224.89) | 0.02 (0.015) | 0.05 (0.011) | −0.29 (0.038) | Dominant | Dominant | Dominant |
Time Horizon 4 years | -€2493.99 (267.06) | 0.03 (0.019) | 0.06 (0.014) | −0.36 (0.044) | Dominant | Dominant | Dominant |
Time Horizon 10 years | -€4552.43 (513.34) | 0.11 (0.057) | 0.11 (0.040) | −0.72 (0.072) | Dominant | Dominant | Dominant |
Time Horizon 15 years | -€5491.36 (746.04) | 0.19 (0.089) | 0.14 (0.059) | −0.96 (0.088) | Dominant | Dominant | Dominant |
Time Horizon 20 years | -€6010.09 (985.99) | 0.28 (0.118) | 0.16 (0.076 | −1.16 (0.111) | Dominant | Dominant | Dominant |
Time Horizon 30 years | -€6184.28 (1387.21) | 0.44 (0.172) | 0.20 (0.104) | −1.41 (0.144) | Dominant | Dominant | Dominant |
Utility tariffs increased 30% | -€2939.66 (300.83) | 0.04 (0.025) | 0.09 (0.024) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Utility tariffs decreased 30% | -€2939.66 (300.83) | 0.04 (0.025) | 0.05 (0.013) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Probability of doctors visit for adverse events 5% | -€2983.18 (269.74) | 0.04 (0.023) | 0.07 (0.019) | −0.43 (0.044) | Dominant | Dominant | Dominant |
Probability of doctors visit for adverse events 15% | -€2824.75 (326.69) | 0.04 (0.027) | 0.07 (0.020) | −0.41 (0.050) | Dominant | Dominant | Dominant |
Probability of switching treatment following doctors visit for adverse events 5% | -€2940.17 (303.80) | 0.04 (0.024) | 0.07 (0.017) | −0.42 (0.051) | Dominant | Dominant | Dominant |
Probability of switching treatment following doctors visit for adverse events 25% | -€2849.86 (334.18) | 0.04 (0.024) | 0.07 (0.018) | −0.41 (0.054) | Dominant | Dominant | Dominant |
Cost of OLAI increased 25% | -€152.19 (302.58) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of OLAI decreased 25% | -€5727.14 (304.63) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Branded drug costs decreased 7.5% | -€2899.05 (296.94) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of concomitant medication increased 25% | -€2934.53 (302.95) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |
Cost of concomitant medication decreased 25% | -€2944.80 (298.74) | 0.04 (0.025) | 0.07 (0.019) | −0.42 (0.049) | Dominant | Dominant | Dominant |